The influence of the hematological complications on the efficiency of the systemic therapy of breast cancer

Medičnì Perspektivi. 2016;21(2):74-77


Journal Homepage

Journal Title: Medičnì Perspektivi

ISSN: 2307-0404 (Print)

Publisher: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"

Society/Institution: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"

LCC Subject Category: Medicine

Country of publisher: Ukraine

Language of fulltext: Ukrainian, Russian, English

Full-text formats available: PDF



Prokhach A.V. (SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» )


Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 9 weeks


Abstract | Full Text

The interest in studying the effect of haematological complications on survival of patients with solid tumors during chemotherapy has increased in recent years. The results of various global studies are ambiguous and often opposite. The objectives of our study was to investigate the dynamics of hematological parameters during the course of chemotherapy, their impact on health outcomes and indicators of survival of patients. Retrospectively, medical records of 110 patients with inoperable breast cancer, who received palliative chemotherapy courses by the scheme taxanes + anthracyclines, were analyzed. Dynamics of neutrophils indicators, hemoglobin, platelets, tumor response according to RECIST criteria of 1.1., as well as the long-term outcomes were studied. It was found that the most intensively level of hemoglobin reduced at the first cycle of treatment (81.1% of patients), later it stabilized (17.7-37.3%) (p<0.05). During the first treatment cycle neutropenia occurs in 71.1-78.2% of patients, thrombocytopenia – in 3.6-5.55%. Later, thrombocytopenia rate reduced to 1.2-1.9%, neutropenia – to 58.3-63.5% (p<0.05). The presence of neutropenia causes significantly positive impact on the results of treatment of patients with metastatic breast cancer. In the presence of neutropenia during chemotherapy, indicators of general and disease-free survival are reliably higher.